Point72 Asia (Singapore) Pte. Ltd. Cue Biopharma, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 27,764 shares of CUE stock, worth $37,203. This represents 0.01% of its overall portfolio holdings.
Number of Shares
27,764
Previous 24,098
15.21%
Holding current value
$37,203
Previous $18.2 Million
65.85%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CUE
# of Institutions
57Shares Held
11.9MCall Options Held
22KPut Options Held
1.2K-
Bleichroeder LP New York, NY5MShares$6.7 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$2.76 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$1.01 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA631KShares$845,9160.0% of portfolio
-
Robertson Stephens Wealth Management, LLC San Francisco, CA479KShares$641,1900.02% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $47.4M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...